6-(4-bromophenyl)-4-ethoxycarbonyl-(2H)-pyridazin-3-one | 149354-29-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(4-bromophenyl)-4-ethoxycarbonyl-(2H)-pyridazin-3-one
• 英文别名: ethyl 3-(4-bromophenyl)-6-oxo-1H-pyridazine-5-carboxylate
• CAS: 149354-29-0
• 化学式: C₁₃H₁₁BrN₂O₃
• 分子量: 323.146
• InChiKey: CESPSJPTILYBIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(4-bromophenyl)-4-ethoxycarbonyl-(2H)-pyridazin-3-one 在 sodium hydroxide 、 potassium carbonate 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 28.0h， 生成 6-(4-Bromo-phenyl)-2-carboxymethyl-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid
  参考文献：
  名称：

  Synthesis of pyridazine acetic acid derivatives possessing aldose reductase inhibitory activity and antioxidant properties

  摘要：

  N-Acetic acid derivatives of 4-carboxy-6-arylpyridazin-3-ones were synthesized for the dual purpose of inhibiting aldose reductase and exhibiting antioxidant properties. All the prepared compounds showed a significant in vitro aldose reductase inhibitory effect (10(-5) M less than or equal to IC50 less than or equal to 10(-4) M). The spatial configuration of the most active derivative 4f (4-i-PrC6H4 at C-6, IC50 = 0 95 x 10(-5) M) was compared with pharmacophore requirements of the aldose reductase inhibitor site using a molecular modeling system. The antioxidant action of 4a-f was also studied in vitro. Compound 4c (4-ClC6H4 at C-6, IC50 = 1.56 x 10(-3) M) was the most effective at scavenging the superoxide anion whereas compound 4a (C6H5 at C-6, IC50 = 1.28 x 10(-3) M) was the most active at inhibiting lipid peroxidation. In addition, biological activities (log 1/IC50) for most of the data sets could be correlated directly to lipophilic, electronic and steric parameters.

  DOI：

  10.1016/0223-5234(94)90074-4
• 作为产物：
  描述：

  2-[2-(4-Bromo-phenyl)-2-oxo-ethyl]-2-hydroxy-malonic acid diethyl ester 在 盐酸肼 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以66%的产率得到6-(4-bromophenyl)-4-ethoxycarbonyl-(2H)-pyridazin-3-one
  参考文献：
  名称：

  Synthesis of pyridazine acetic acid derivatives possessing aldose reductase inhibitory activity and antioxidant properties

  摘要：

  N-Acetic acid derivatives of 4-carboxy-6-arylpyridazin-3-ones were synthesized for the dual purpose of inhibiting aldose reductase and exhibiting antioxidant properties. All the prepared compounds showed a significant in vitro aldose reductase inhibitory effect (10(-5) M less than or equal to IC50 less than or equal to 10(-4) M). The spatial configuration of the most active derivative 4f (4-i-PrC6H4 at C-6, IC50 = 0 95 x 10(-5) M) was compared with pharmacophore requirements of the aldose reductase inhibitor site using a molecular modeling system. The antioxidant action of 4a-f was also studied in vitro. Compound 4c (4-ClC6H4 at C-6, IC50 = 1.56 x 10(-3) M) was the most effective at scavenging the superoxide anion whereas compound 4a (C6H5 at C-6, IC50 = 1.28 x 10(-3) M) was the most active at inhibiting lipid peroxidation. In addition, biological activities (log 1/IC50) for most of the data sets could be correlated directly to lipophilic, electronic and steric parameters.

  DOI：

  10.1016/0223-5234(94)90074-4

文献信息

• 2-pyrrolidinones, pharmaceutical compositions containing these compounds
  申请人：Thomae; Karl

  公开号：US05455348A1

  公开（公告）日：1995-10-03

  The invention relates to cyclic imino derivatives of general formula B--X.sub.5 --X.sub.4 --X.sub.3 --X.sub.2 --X.sub.1 --A--Y--E(I) wherein A, B, E, X.sub.2 to X.sub.5 and Y are defined as in claim 1, the stereoisomers, tautomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation-inhibiting effects, pharmaceutical compositions which contain these compounds and processes for preparing them.

  该发明涉及一般式B--X.sub.5 --X.sub.4 --X.sub.3 --X.sub.2 --X.sub.1 --A--Y--E(I)的环状亚胺衍生物，其中A、B、E、X.sub.2到X.sub.5和Y的定义如权利要求1中所述，其立体异构体、互变异构体、混合物和盐，特别是其与无机或有机酸或碱形成的生理上可接受的盐，具有有价值的药理特性，优选具有聚集抑制作用的药物组合物，包含这些化合物的制备方法。
• Heterobiarly derivatives and pharmaceutical compositions thereof
  申请人：Karl Thomae GmbH

  公开号：US05418233A1

  公开（公告）日：1995-05-23

  Heterobiaryl derivatives of the formula R.sub.1 NH--X.sub.1 --X.sub.2 --X.sub.3 --Y.sub.1 --Y.sub.2 --Y.sub.3 --Y.sub.4 --E (I) wherein R.sub.1, X.sub.1 to X.sub.3 and Y.sub.1 to Y.sub.4 are as defined herein, the tautomers, stereoisomers and mixtures thereof, and the salts, particularly the physiologically acceptable salts, thereof with organic or inorganic acids or bases. The derivatives have valuable pharmacological properties, such as inhibiting cell-cell aggregation and cell-matrix interactions.

  公式R.sub.1 NH--X.sub.1 --X.sub.2 --X.sub.3 --Y.sub.1 --Y.sub.2 --Y.sub.3 --Y.sub.4 --E（I）的Heterobiaryl衍生物，其中R.sub.1，X.sub.1至X.sub.3和Y.sub.1至Y.sub.4如本文所定义，其互变异构体，立体异构体和它们的混合物，以及其与有机或无机酸或碱的盐，特别是生理上可接受的盐。这些衍生物具有有价值的药理特性，如抑制细胞-细胞聚集和细胞-基质相互作用。
• Cyclische Iminoderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
  申请人：Dr. Karl Thomae GmbH

  公开号：EP0528369A2

  公开（公告）日：1993-02-24

  Die Erfindung betrifft cyclische Iminoderivate der allgemeinen Formel         B - X₅ - X₄ - X₃ - X₂ - X₁ - A - Y - E   ,(I) in der A, B, E, X₂ bis X₅ und Y wie im Anspruch 1 definiert sind, deren Stereoisomere, deren Tautomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, welche wertvolle pharmakologische Eigenschaften aufweisen, vorzugsweise aggregationshemmende Wirkungen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung.

  本发明涉及通式如下的环状亚氨基衍生物 b - x₅ - x₄ - x₃ - x₂ - x₁ - a - y - e ,(i) 其中 A、B、E、X₂至 X₅ 和 Y 如权利要求 1 所定义，它们的立体异构体、同分异构体、混合物和盐，特别是它们与无机或有机酸或碱的生理相容盐，这些盐具有重要的药理特性，最好是抗聚集作用，含有这些化合物的药物及其制备工艺。
• Heterobiarylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
  申请人：Dr. Karl Thomae GmbH

  公开号：EP0537696A1

  公开（公告）日：1993-04-21

  Die Erfindung betrifft Heterobiarylderivate der allgemeinen Formel         R₁NH - X₁ - X₂ - X₃ - Y₁ - Y₂ - Y₃ - Y₄ - E   ,(I) in der R₁, X₁ bis X₃ und Y₁ bis Y₄ wie im Anspruch 1 definiert sind, deren Tautomere, deren Stereoisomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, welche wertvolle pharmakologische Eigenschaften aufweisen, vorzugsweise aggregationshemmende Wirkungen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung.

  本发明涉及通式如下的杂环丁基衍生物 r₁nh - x₁ - x₂ - x₃ - y₁ - y₂ - y₃ - y₄ - e ,(i) 在 R₁、X₁至 X₃和 Y₁ 至 Y₄ 如权利要求 1 所定义，它们的同分异构体、立体异构体、混合物和它们的盐，特别是它们与无机或有机酸或碱的生理耐受盐，具有有价值的药理特性，最好是抗聚集作用，含有这些化合物的药物和它们的制备工艺。
• US5418233A
  申请人：——

  公开号：US5418233A

  公开（公告）日：1995-05-23